Mednax Inc (MD)
Return on equity (ROE)
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (ttm) | US$ in thousands | -99,069 | -253,836 | -233,004 | -51,697 | -41,526 | 112,420 | 102,875 | 101,729 | 66,578 | 84,435 | 84,502 | 92,377 | 130,964 | 19,152 | -52,687 | -760,134 | -796,488 | -722,861 | -1,937,737 | -1,273,546 |
| Total stockholders’ equity | US$ in thousands | 764,938 | 732,492 | 706,461 | 856,196 | 849,061 | 967,985 | 942,375 | 909,771 | 891,632 | 858,667 | 845,430 | 877,076 | 896,692 | 845,466 | 808,906 | 766,759 | 747,717 | 804,761 | 826,570 | 1,487,400 |
| ROE | -12.95% | -34.65% | -32.98% | -6.04% | -4.89% | 11.61% | 10.92% | 11.18% | 7.47% | 9.83% | 10.00% | 10.53% | 14.61% | 2.27% | -6.51% | -99.14% | -106.52% | -89.82% | -234.43% | -85.62% |
December 31, 2024 calculation
ROE = Net income (ttm) ÷ Total stockholders’ equity
= $-99,069K ÷ $764,938K
= -12.95%
Mednax Inc's return on equity (ROE) has shown significant fluctuations over the period from March 31, 2020, to December 31, 2024. The company experienced negative ROE values for the majority of 2020 and early 2021, indicating a decrease in profitability relative to its shareholders' equity.
However, starting from the second half of 2021, there was a notable improvement in ROE, with values turning positive and increasing steadily through 2022 and 2023. This positive trend suggests an enhanced ability of the company to generate profits from the shareholders' investments.
Despite the positive momentum in 2022 and 2023, Mednax Inc faced a decline in ROE in the latter half of 2023 and throughout 2024, with negative values recorded once again. These negative ROE figures may indicate challenges in generating profits compared to the shareholders' equity during this period.
Overall, the analysis highlights the volatility in Mednax Inc's ROE performance, showcasing periods of both improvement and decline in profitability relative to the shareholders' equity over the reviewed timeframe.
Peer comparison
Dec 31, 2024